Blood study on COVID-19 and cancer withdrawn before starting
NCT ID NCT04953312
First seen Mar 17, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This study was designed to learn how the protein calprotectin changes blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare cells from patients and healthy adults in lab tests. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gustave Roussy Institut
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.